Mydriacyl
(Tropicamide)ApprovedSmall molecule
Mydriacyl is one of 63 small molecule programs targeting Cataract. It is currently in Approved.
3
Indications
11
Total Trials
0
Active Trials
62
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
63 competitors in Cataract
#DrugCompanyPhaseTrials
1Eylea
RegeneronApproved
Avelox
BayerApproved
Decadron
AAspen Global Incorporated
Approved
Bromday
BBausch Health Americas, Inc.
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Lovenox
SanofiApproved
Toradol
RocheApproved
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Levaquin
WWim Janssens
Approved
Versed
CConrado Roberto Hoffmann Filho
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Intraocular Pressure2 trials
Parkinson's Disease1 trial
Children1 trial
Cycloplegic Refraction Among Children
Completed·—·Phase 4·NCT05442801·55 enrolled
Esotropia1 trial
Cycloplegic Refraction in Pediatric Patients With Esotropia
Unknown status·—·Phase 4·NCT06077682·100 enrolled
5 more indications
Oxygenation1 trial
Unspecified1 trial
Regulatory
FDA Approval Timeline[4]
Jan 1, 1982
MYDRIACYL
NDA NDA012111
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tropicamide. EMBL-EBI & Wellcome Sanger Institute.
- [4]
- [5]